- In May 2024, Jagsonpal Pharmaceuticals Limited, an Indian pharmaceutical company, launched MemUp HRT, a US FDA-approved bioidentical hormone therapy. This therapy features a single-pill solution combining bioidentical estradiol and progesterone, with support available in nine regional languages. The introduction of MemUp HRT aims to provide more personalized and efficient solutions for hormonal imbalances and related health issues
- In February 2024, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. This surge underscores the growing emphasis on personalized medicine, which tailors treatments to individual characteristics. In the context of bioidentical hormones, this approach involves customizing hormone replacement therapies based on a patient's specific hormonal profile, enhancing treatment efficacy and minimizing side effects
